Jci_page_head_homepage_01 Jci_page_head_homepage_02
Nichole R. Klatt, Francois Villinger, Pavel Bostik, Shari N. Gordon, Lara Pereira, Jessica C. Engram, Ann Mayne, Richard M. Dunham, Benton Lawson, Sarah J. Ratcliffe, Donald L. Sodora, James Else, Keith Reimann, Silvija I. Staprans, Ashley T. Haase, Jacob D. Estes, Guido Silvestri, Aftab A. Ansari
Published in Volume 118, Issue 6
J Clin Invest. 2008; 118(6):2039–2049 doi:10.1172/JCI33814
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 1
In vivo CD4+ T cell depletion in SIV-infected SMs.

(A) Representative flow cytometric contour plots (x axis, CD3; y axis, CD4) of CD4+ T cells in PBMCs, LNs, BM, RBs, and BAL at 30 d before depleting antibody treatment and nadir CD4+ T cell fraction (10–14 d) after depleting antibody treatment was initiated. Numbers denote percentage of cells within the boxed regions. (B) Longitudinal assessment of the percent and absolute number of CD3+CD4+ T cells for each animal through 240 d after depletion. (C) Longitudinal assessment of the percent of circulating CD14+ monocytes for each animal through 150 d after depletion. Depleting anti-CD4 Ab was administered at 0, 3, 7, and 10 d (represented by tick marks and dotted lines). (D) Longitudinal assessment of the percent of CD3+CD4+ T cells in LNs, BM, RBs, and BAL at –30, 14, 60, and 120 d.